Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "US-FDA"

251 News Found

Microbion gets US patent for the use of inhaled pravibismane for pulmonary infections
News | April 06, 2023

Microbion gets US patent for the use of inhaled pravibismane for pulmonary infections

Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039


GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme
News | April 03, 2023

GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme

SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties


Granules India receives ANDA approval for Gabapentin Tablets
Drug Approval | March 30, 2023

Granules India receives ANDA approval for Gabapentin Tablets

Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults


Granules India inaugurates packaging facility in Virginia
Supply Chain | March 30, 2023

Granules India inaugurates packaging facility in Virginia

The facility is over 79,000 square feet and is equipped with packaging lines


Bliss GVS Pharma gets 3 minor observations from USFDA for Palghar unit
Drug Approval | March 19, 2023

Bliss GVS Pharma gets 3 minor observations from USFDA for Palghar unit

The observations are procedural in nature


Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
Drug Approval | March 13, 2023

Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division

The company will be submitting the responses to US FDA observations within stipulated timeline


Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg
Drug Approval | February 27, 2023

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.


SERDA therapeutics submits IND for wound debridement agent
Drug Approval | February 24, 2023

SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.


Briefs: Alkem and Krsnaa Diagnostics
News | February 24, 2023

Briefs: Alkem and Krsnaa Diagnostics

Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.


Lupin receives EIR from USFDA for injectable facility in Nagpur
News | February 18, 2023

Lupin receives EIR from USFDA for injectable facility in Nagpur

The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022